[Efficacy, safety and cost of eribulin in patients with metastatic breast cancer].

Fiche publication


Date publication

septembre 2015

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CHAIGNEAU Loïc, Dr MENEVEAU Nathalie, Pr NERICH Virginie, Pr PIVOT Xavier


Tous les auteurs :
Paillard MJ, Curtit E, Dobi E, Mansi L, Bazan F, Villanueva C, Chaigneau L, Montcuquet P, Meneveau N, Thiery-Vuillemin A, Nerich V, Pivot X

Résumé

Eribulin gained its approval in March 2011 for the treatment of patients with locally advanced or metastatic breast cancer (MBC) whose disease has progressed despite anthracycline and taxane-containing regimens. This study retrospectively assessed the efficacy, safety and cost of this treatment for all patients with MBC treated by eribulin in Franche-Comte. Ninety-four patients received eribulin between July 2006 and October 2013. The median age was 62 years (35-83). Median overall survival was 10.3 months [95% CI: 7.6 to 17.9]. Median progression-free-survival was 3.8 months [95% CI: 2.9 to 5.0]. Clinical benefit was obtained in 55% evaluable patients [95% CI: 43.1 to 66.9] by RECIST criteria. Most common grade 3-4 adverse events (AEs) were neutropenia (38%), asthenia (10%) and peripheral neuropathy (7%). Median cost of the treatment was 9767 euro per patient (6344-17,517). This analysis found similar results to the EMBRACE study despite less selected population. A medico-economic evaluation cost-utility type would assess the effectiveness of this strategy compared to standard treatments.

Référence

Bull Cancer. 2015 Sep;102(9):737-48